Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | THRB | P10828 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27034337 | 0.87 | PDK2 (0.42) | SMN1; SMN2THRBGAAMAPTPDK2 | |
| SCHEMBL16399632 | 0.87 | SMN1; SMN2 (0.61) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL314695 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL10189882 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL19899477 | 0.82 | SMN1; SMN2 (0.57) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL8283578 | 0.82 | SMN1; SMN2 (0.55) | SMN1; SMN2THRBGAAMAPTPDK2 | |
| SCHEMBL25124309 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL10189881 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL9965924 | 0.80 | NR1H2 (0.40) | SMN1; SMN2THRBGAAMAPTHDAC4 | |
| SCHEMBL1970981 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2THRBGAAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023055178-A1 | NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME | 주식회사 넥스트젠바이오사이언스 | 2023-04-06 | — | — | WO | disclosed |
| US-9663495-B2 | Triazolone derivatives or salts thereof and pharmaceutical composition comprising the same | YUHAN CORPORATION (KR) | 2017-05-30 | — | — | US | disclosed |
| US-9663495-B2 | Triazolone derivatives or salts thereof and pharmaceutical composition comprising the same | YUHAN CORPORATION (KR) | 2017-05-30 | — | — | US | disclosed |
| US-9663495-B2 | Triazolone derivatives or salts thereof and pharmaceutical composition comprising the same | YUHAN CORPORATION (KR) | 2017-05-30 | — | — | US | disclosed |
| US-20160068515-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2016-03-10 | — | — | US | disclosed |
| US-20160068515-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2016-03-10 | — | — | US | disclosed |
| US-20160068515-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2016-03-10 | — | — | US | disclosed |
| EP-2989093-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Yuhan Corporation (KR) | 2016-03-02 | — | — | EP | disclosed |
| WO-2014175621-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068515-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | GPR119, GPR88, GCGR | SMN1; SMN2 4157/4885THRB 445/4885GAA 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.